Global (United States, European Union and China) PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2019-2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market


PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018. The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. In 2019, the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor is 1205 million US$ and it will reach 8777.6 million US$ in 2025, growing at a CAGR of 32.8% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for PARP (Poly ADP-Ribose Polymerase) Inhibitor. This report studies the global market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the PARP (Poly ADP-Ribose Polymerase) Inhibitor production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019

Market Segmentation: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

Segmentation by Product Type : Breakdown of data from year 2014 to 2019 and forecast until 2025:
Lynparza
Zejula
Rubraca
Talzenna
Other

Segmentation by Application : Breakdown of data from year 2014 to 2019 and forecast until 2025:
Ovarian Cancer
Breast Cancer
Other

Top Companies & Key Players: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

The report offers a detailed analysis of several leading PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers including:
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer

Key Insights Covered: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
1.  North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.

Research Methodology: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other